Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Martin F. Kaiser*, Andrew Hall, Katrina Walker, Amy Sherborne, Ruth M. De Tute, Nicola Newnham, Sadie Roberts, Emma Ingleson, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah R. Brown, Matthew W. Jenner

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

20 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences